Opinion
Video
Author(s):
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
City of Hope CAR T-Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes
Best Practices in Treating Early-Stage NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium